1.            Maimon, O. et al. The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report. Anticancer Res. 44, 3543–3550 (2024).

2.            Christopoulos, P. et al. Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer. JCO Precis. Oncol. 8, (2024).

3.            Benguigui, M. et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell 42, 253-265.e12 (2024).

4.            Bar, J. et al. Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy. Front. Immunol. 15, (2024).

5.            Lotem, M. et al. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin. Cancer Res. 15, 4968–4977 (2009).

6.            Jacover, A. et al. Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer. Cancer Rep. 6, (2023).

7.            Robert, C. et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J. Clin. Oncol. 41, 3998–4003 (2023).

8.            Talmon, A. et al. Dupilumab for cancer-associated refractory pruritus. J. Allergy Clin. Immunol. Glob. 2, (2023).

9.            Friedman, N. et al. Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions. Sci. Transl. Med. 15, (2023).

10.          Stejerean-Todoran, I. et al. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells. Neuro. Oncol. 25, 674–686 (2023).

11.          Schaft, N. et al. The future of affordable cancer immunotherapy. Front. Immunol. 14, (2023).

12.          Babiker, H. et al. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin. Cancer Res. 28, 5079–5087 (2022).

13.          Molho-Pessach, V. et al. Giant congenital melanocytic naevus with a novel CUX1–BRAF fusion mutation treated with trametinib. Br. J. Dermatol. 187, 1052–1054 (2022).

14.          Shreberk-Hassidim, R. et al. The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma. Immunol. Res. 70, 793–799 (2022).

15.          Sidlik Muskatel, R., Pillar, N., Godefroy, J., Lotem, M. & Goldstein, G. Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy. Front. Pediatr. 10, (2022).

16.          Shreberk-Hassidim, R. et al. Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma. Dermatol. Ther. 35, (2022).

17.          Zer, A. et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann. Oncol. 33, 720–727 (2022).

18.          Labes, S. et al. Machine-learning of complex evolutionary signals improves classification of SNVs. NAR Genomics Bioinforma. 4, (2022).

19.          Ronen, D. et al. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines 10, (2022).

20.          Long, G. V et al. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Ann. Oncol. 33, 204–215 (2022).

21.          Dalle, S. et al. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer 21, (2021).

22.          Avner, M. et al. COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma. Eur. J. Nucl. Med. Mol. Imaging 48, 2659–2660 (2021).

23.          Hajaj, E. et al. Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions. Cancer Immunol. Res. 9, 637–650 (2021).

24.          Ghosh, S. et al. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Rep. 35, (2021).

25.          Bottomley, A. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 655–664 (2021).

26.          Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 643–654 (2021).

27.          Maddalena, M. et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc. Natl. Acad. Sci. U. S. A. 118, (2021).

28.          Kalaora, S. et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138–143 (2021).

29.          Peri, A. et al. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. J. Clin. Invest. 131, (2021).

30.          Ferrucci, P. F. et al. KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J. Immunother. Cancer 8, (2020).

31.          Kalaora, S. et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat. Commun. 11, (2020).

32.          Kucukkaraduman, B. et al. Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells. ACS Med. Chem. Lett. 11, 928–932 (2020).

33.          Hirshoren, N. et al. Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. PLoS One 15, (2020).

34.          Hajaj, E. et al. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. Elife 9, (2020).

35.          Hadash-Bengad, R. et al. Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study. Front. Oncol. 10, (2020).

36.          Tsur, N. et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J. Transl. Med. 17, (2019).

37.          Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239–1251 (2019).

38.          Pollack, R. M., Kagan, M., Lotem, M. & Dresner-Pollak, R. Baseline TSH level is associated with risk of anti–PD-1–induced thyroid dysfunction. Endocr. Pract. 25, 824–829 (2019).

39.          Ascierto, P. A. et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 25, 941–946 (2019).

40.          Boussemart, L. et al. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. J. Am. Acad. Dermatol. 80, 1780–1782 (2019).

41.          Weinstein-Marom, H. et al. Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells. J. Immunother. 42, 43–50 (2019).

42.          Levin, N. et al. Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40. J. Immunol. 201, 2959–2968 (2018).

43.          Kalaora, S. et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 8, 1366–1375 (2018).

44.          Filippou, P. S. et al. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clin. Chem. Lab. Med. 56, 1945–1953 (2018).

45.          Fellner, A. et al. Neurologic complications of immune checkpoint inhibitors. J. Neurooncol. 137, 601–609 (2018).

46.          Eisenberg, G. et al. Soluble SLAMF6 receptor induces strong CD8\+ T-cell effector function and improves anti-melanoma activity in vivo. Cancer Immunol. Res. 6, 127–138 (2018).

47.          Jacquelot, N. et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8, (2017).

48.          Schachter, J. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390, 1853–1862 (2017).

49.          Zick, A. et al. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Med. (United States) 96, (2017).

50.          Cohen, J. E. et al. Adoptive cell therapy: Past, present and future. Immunotherapy 9, 183–196 (2017).

51.          Senses, K. M. et al. Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. Medchemcomm 8, 88–95 (2017).

52.          Kuint, R. et al. Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report. Respir. Med. Case Reports 20, 95–97 (2017).

53.          Levin, N. et al. Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. J. Immunother. 40, 39–50 (2017).

54.          Sade-Feldman, M. et al. Clinical significance of circulating CD33+ CD11bHLA-DR myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin. Cancer Res. 22, 5661–5672 (2016).

55.          Engelstein, R. et al. Immune monitoring of patients treated with a whole-cell melanoma vaccine engineered to express 4-1BBL. J. Immunother. 39, 321–328 (2016).

56.          Ollech, A. et al. Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. Int. J. Dermatol. 55, 473–478 (2016).

57.          Lotem, M. et al. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. J. Immunol. Res. 2016, (2016).

58.          Weinstein-Marom, H. et al. Membrane-attached cytokines expressed by mRNA electroporation act as potent T-cell adjuvants. J. Immunother. 39, 60–70 (2016).

59.          Barak, V. et al. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. Anticancer Res. 35, 6755–6760 (2015).

60.          Pato, A. et al. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clin. Exp. Immunol. 182, 220–229 (2015).

61.          Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

62.          Uzana, R. et al. Human T cell crosstalk is induced by tumor membrane transfer. PLoS One 10, (2015).

63.          Shtivelman, E. et al. Pathways and therapeutic targets in melanoma. Oncotarget 5, 1701–1752 (2014).

64.          Eisenberg, G. et al. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J. Immunol. 190, 5856–5865 (2013).

65.          Yaacov, B. et al. Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. J. Gen. Virol. 93, 1664–1672 (2012).

66.          Lazar, I. et al. The clinical effect of the inhibitor of apopotosis protein livin in melanoma. Oncology 82, 197–204 (2012).

67.          Uzana, R. et al. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8 + T cell clones. J. Immunol. 188, 632–640 (2012).

68.          Lotem, M., Merims, S., Frank, S., Ospovat, I. & Peretz, T. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma]. Harefuah 151, 585-588,604 (2012).

69.          Lotem, M. et al. HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine. Tissue Antigens 78, 203–207 (2011).

70.          Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).

71.          Eisenberg, G. et al. Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response. Cell. Immunol. 266, 98–103 (2010).

72.          Lazar, I. et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein livin. J. Virol. 84, 639–646 (2010).

73.          Bosch, J. J. et al. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol. Immunother. 59, 103–112 (2010).

74.          Frenkel, S. et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br. J. Ophthalmol. 93, 1042–1046 (2009).

75.          Kadouri, L. et al. Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Fam. Cancer 8, 29–32 (2009).

76.          Gross, M., Maly, B., Maly, A., Lotem, M. & Eliashar, R. Metastatic Malignant Melanoma Involving the Parotid Lymph Node Region: A Clinicopathologic Report of 5 Cases. J. Oral Maxillofac. Surg. 66, 809–813 (2008).

77.          Machlenkin, A. et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Res. 68, 2006–2013 (2008).

78.          Levy, A. et al. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cell. Immunol. 250, 24–30 (2007).

79.          Molho-Pessach, V. & Lotem, M. Ultraviolet radiation and cutaneous carcinogenesis. Current Problems in Dermatology vol. 35 14–27 (2007).

80.          Molho-Pessach, V. & Lotem, M. Viral carcinogenesis in skin cancer. Current Problems in Dermatology vol. 35 39–51 (2007).

81.          Bosch, J. J. et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4+ T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67, 4499–4506 (2007).

82.          Salah, Z. et al. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol. Cancer Res. 5, 229–240 (2007).

83.          Lotem, M. et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J. Immunother. 29, 616–627 (2006).

84.          Peters, S. et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Ann. Oncol. 17, 578–583 (2006).

85.          Enk, C. D., Lotem, M., Gimon, Z. & Hochberg, M. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res. 14, 361–365 (2004).

86.          Frankenburg, S. et al. Recombinant hydrophilic human gp100: Uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients. Immunol. Lett. 94, 253–259 (2004).

87.          Hodak, E. et al. An open trial of climatotherapy at the dead sea for patch-stage mycosis fungoides. J. Am. Acad. Dermatol. 51, 33–38 (2004).

88.          Lotem, M. et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br. J. Cancer 90, 773–780 (2004).

89.          Lieberman, S., Goldin, E., Lotem, M. & Bloom, A. I. Irrigation of the bile ducts with chilled saline during percutaneous radiofrequency ablation of a hepatic ocular melanoma metastasis. Am. J. Roentgenol. 183, 596–598 (2004).

90.          Gelbart, Y. et al. Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expr. Purif. 34, 183–189 (2004).

91.          Nachmias, B. et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res. 63, 6340–6349 (2003).

92.          Lotem, M. et al. Cytogenetic analysis of melanoma cell lines: Subclone selection in long-term melanoma cell cultures. Cancer Genet. Cytogenet. 142, 87–91 (2003).

93.          Lotem, M. et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol. Oncol. 88, 45–50 (2003).

94.          Lotem, M. et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). Br. J. Cancer 86, 1534–1539 (2002).

95.          Hochberg, M., Lotem, M., Gimon, Z., Shiloni, E. & Enk, C. D. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br. J. Dermatol. 146, 244–249 (2002).

96.          Markel, G. et al. CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. J. Immunol. 168, 2803–2810 (2002).

97.          Lotem, M. et al. Special section on nonparametric approach to time series analysis. Ann. Inst. Stat. Math. 54, 169 (2002).

98.          Lotem, M. et al. Kindler syndrome complicated by squamous cell carcinoma of the hard palate: Successful treatment with high-dose radiation therapy and granulocyte-macrophage colony-stimulating factor [18]. Br. J. Dermatol. 144, 1284–1286 (2001).

99.          Pappo, I., Lotem, M., Klein, M. & Orda, R. Bolus high dose interleukin-2 for the treatment of malignant melanoma. Isr. Med. Assoc. J. 3, 169–173 (2001).

100.        Hazzan, D. et al. Primary rectal malignant melanoma: Report of two cases. Tech. Coloproctol. 5, 51–54 (2001).

101.        Yakobson, E. et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur. J. Hum. Genet. 8, 590–596 (2000).

102.        Lyass, O. et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer 89, 1037–1047 (2000).

103.        Lotem, M. et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. 136, 1475–1480 (2000).

104.        Klein, M. et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: A pilot study. NuklearMedizin 39, 56–61 (2000).

105.        Hirshberg, B. et al. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma. Am. J. Hematol. 60, 143–147 (1999).

106.        Lotem, M., Shiloni, E., Ingber, A. & Peretz, T. Active specific immunotherapy of malignant melanoma. Harefuah 133, 122–126 (1997).

107.        Tsur, A., Sazbon, L. & Lotem, M. Relationship between muscular tone, movement and periarticular new bone formation in postcoma-unaware (PC-U) patients. Brain Inj. 10, 259–262 (1996).

108.        Lotem, M., Tamir, G., Loven, D., David, M. & Hauben, D. Multiple basal cell carcinomas of the leg after recurrent erysipelas and chronic lymphedema. J. Am. Acad. Dermatol. 31, 812–813 (1994).

109.        Lotem, M., Trattner, A. & Ingber, A. Paraneoplastic Pemphigus: Reevaluation of a Case From the Past. Arch. Dermatol. 130, 1454 (1994).

110.        Tsur, A., Sazbon, L. & Lotem, M. Influence of muscle tone and force on ossification in postcomatose patients. Harefuah 123, 86-89,156-157 (1992).

111.        LOTEM, M., TRATTNER, A., KAHANOVICH, S., ROTEM, A. & SANDBANK, M. MULTIPLE DERMAL CYLINDROMA UNDERGOING A MALIGNANT TRANSFORMATION. Int. J. Dermatol. 31, 642–644 (1992).

112.        Lotem, M. et al. Letter to the editor [3]. J. Bone Jt. Surg. - Ser. A 73, 472 (1991).

113.        Lotem, M., Ingber, A., Segal, R. & Sandbank, M. Generalized pustular drug rash induced by hydroxychloroquine. Acta Derm. Venereol. 70, 250–251 (1990).

114.        Katzenelson, V., Lotem, M. & Sandbank, M. Familial lichen planus. Dermatologica 180, 166–168 (1990).

115.        Halevy, S., Arie, R., Ingber, A., Lotem, M. & Sandbank, M. Analysis of lithogenous factors in lichen planus. Acta Derm. Venereol. 70, 441–442 (1990).

116.        Lotem, M., Ingber, A., Sandbank, M. & Hazaz, B. Lichen Planus Pemphigoides With Features of Lichen Planus and Pemphigus Vulgaris. Arch. Dermatol. 125, 707–708 (1989).

117.        Lotem, M., Katzenelson, V., Sandbank, M., Hod, M. & Sandbank, M. Impetigo herpetiformis: A variant of pustular psoriasis or a separate entity? J. Am. Acad. Dermatol. 20, 338–341 (1989).

118.        Lotem, M., Ingber, A., Filhaber, A. & Sandbank, M. Skin infection provoked by coagulase-negative Staphylococcus resembling gram-negative folliculitis. Cutis 42, 443–444 (1988).

119.        Davidovitch, E., Lotem, M. & Hallel, T. Malignant fibrous histiocytoma. Harefuah 115, 13–15 (1988).

120.        Sagiv, P., Lotem, M., Solan, H. & Hallel, T. Metatarsus adductus--incidence and treatment. Harefuah 110, 394–397 (1986).

121.        Houpt, J. B. et al. Spontaneous osteonecrosis of the medial tibial plateau. J. Rheumatol. 9, 81–90 (1982).

122.        Groswasser, Z., Lotem, M. & Mendelson, L. Treatment of femoral fractures in patients with craniocerebral injury. Int. Surg. 67, 556–558 (1982).

123.        Greyson, N. D., Lotem, M. M., Gross, A. E. & Houpt, J. B. Radionuclide evaluation of spontaneous femoral osteonecrosis. Radiology 142, 729–735 (1982).

124.        Lotem, M. & Davidovitz, E. Malignant fibrous histiocytoma. Harefuah 98, 216-218+239 (1980).

125.        Conforty, B. & Lotem, M. Ossicles in human menisci: report of two cases. Clin. Orthop. Relat. Res. 272–275 (1979).

126.        Lotem, M., Bernheim, J. & Conforty, B. Spontaneous rupture of tendons. A complication of hemodialyzed patients treated for renal failure. Nephron 21, 201–208 (1978).

127.        Lotem, M. Medical aspects and prevention of road accidents and the treatment of the injured. Fam. Physician 5, 36 (1976).

128.        Lotem, M. & Conforty, B. High pressure injection injuries of the hand (Hebrew). Harefuah 89, 213-215+239 (1975).

129.        Lotem, M. & Wolloch, J. Postoperative peripheral nerve injury. Harefuah 88, 379–380 (1975).

130.        Lotem, M. & Selenfreund, M. Hemangiomatosis of the tibia (Hebrew). Harefuah 88, 464-465+495 (1975).

131.        Lotem, M. & Solzi, P. The carpal tunnel syndrome (Hebrew). Fam. Physician 5, 61-63+12 (1975).

132.        Lotem, M., Robson, M. D. & Rosenfeld, J. B. Spontaneous rupture of the quadriceps tendon in patients on chronic haemodialysis. Ann. Rheum. Dis. 33, 428–429 (1974).

133.        Lotem, M., Maor, P. & Levi, M. Rupture of the extensor tendons of the hand in lupus erythematosus disseminatus. Ann. Rheum. Dis. 32, 457–459 (1973).

134.        Levy, M., Pauker, M., Lotem, M., Seelenfreund, M. & Fried, A. High tibial osteotomy: a follow up study and description of a modified technic. CLIN.ORTHOP. 93, 274–277 (1973).

135.        Pauker, M., Lotem, M., Levy, M. & Luria, M. BCG arthritis and osteomyelitis. Harefuah 83, 429–432 (1972).

136.        Lotem, M., Fried, A., Solzi, P. & Natanson, T. Saturday night palsy. Harefuah 83, 328 (1972).

137.        Maor, P., Levy, M., Lotem, M. & Fried, A. Iatrogenic Volkmann’s ischemia--a result of pressure-transfusion. Int. Surg. 57, 415–416 (1972).

138.        Fried, A. & Lotem, M. Local infiltration anesthesia for meniscectomy. Clin. Orthop. Relat. Res. 87, 204–205 (1972).

139.        Lotem, M., Maor, P. & Fried, A. Posterior interosseous nerve palsy. Harefuah 81, 377–379 (1971).

140.        Lotem, M. & Fried, A. Operative treatment of degenerative tears of the semilunar cartilage. A follow-up study. Isr. J. Med. Sci. 7, 733–737 (1971).

141.        Lotem, M., Maor, P., Haimoff, H. & Woloch, Y. Lumbar hernia at an iliac bone graft donor site. A case report. Clin. Orthop. Relat. Res. 80, 130–132 (1971).

142.        Lotem, M. et al. Radial palsy following muscular effort. A nerve compression syndrome possibly related to a fibrous arch of the lateral head of the triceps. J. Bone Joint Surg. Br. 53, 500–506 (1971).

143.        Lotem, M. & Solsi, P. Transient radial palsy following muscular effort. Harefuah 78, 490–491 (1970).

144.        Levy, M., Lotem, M. & Fried, A. The Laurence-Moon-Biedl-Bardet syndrome. Report of three cases in a Jewish Yemenite family. J. Bone Joint Surg. Br. 52, 318–324 (1970).